Healthcare Industry News:  sinusitis 

Biopharmaceuticals Distribution Generics

 News Release - October 4, 2006

Auriga Executes Agreement Naming River's Edge Pharmaceuticals as Authorized Generic Distributor of Extendryl and Levall

Contract with Leading Distributor Provides Key Strategic Advantages and Protection in Generic-Drug Marketplace

NORCROSS, Ga.--(HSMN NewsFeed)--Auriga Laboratories, Inc. (OTCBB:ARGA ), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, has executed a term sheet for an agreement authorizing River's Edge Pharmaceuticals, LLC to be the exclusive generic drug distributor of the Company's ExtendrylŽ and LevallŽ prescription product lines.

The proposed agreement is designed to provide a number of notable strategic advantages to protect and maximize Auriga's product revenue as it moves into the marketplace for generic versions of its drug brands.

"The agreement with River's Edge is expected to prevent sizable market erosion and maintain market exclusivity at leading retailers around the United States," said Philip S. Pesin, Chief Executive Officer of Auriga. "We expect it will allow us to maintain a significant percentage of our current market share and to maintain important controls over the revenue base of our popular prescription common cold remedies."

The current agreement with River's Edge includes Auriga's recently acquired LevallŽ family of common cold remedy prescription drug products, which generated approximately $9.7 million of sales in 2005 and $9.6 million of sales in 2004. The LevallŽ product line includes four trademarked lines that address medical needs in the multibillion-dollar market for respiratory and common cold ailments. The existing Levall products treat symptoms such as cough, chest congestion and stuffy nose from the common cold, flu, or other breathing illnesses such as sinusitis and bronchitis.

Licensing of the LevallŽ brand, in addition to the Company's proven ExtendrylŽ lines, furthers Auriga's business plan to capitalize on high-growth opportunities in the pharmaceutical industry through aggressive sales, integrated marketing and application of proprietary in-house drug development capabilities.

About River's Edge Pharmaceuticals

River's Edge Pharmaceuticals, LLC is a value priced company that brings niche products to market. We enhance the profitability of our trading partners. The company has experienced rapid growth since its inception in 2003. We will continue to bring such products to market. In addition, we partner with like minded companies to help them protect and bring value to their markets.

About Auriga Laboratories(TM)

Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the ExtendrylŽ and LevallŽ families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases. Auriga's product portfolio also consists of Aquoral(TM) for the treatment of Xerostomia. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. For an informational video overview, visit http://www.trilogy-capital.com/tcp/auriga/video.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the Company's ability to increase its sales force and the success of such sales force in selling our products in light of competitive and other factors, the regulatory status and/or regulatory compliance of our products, our ability to secure additional financing, our ability to sustain market acceptance for our products, our dependence on collaborators, our ability to find and execute strategic transactions, our potential exposure to litigation, our exposure to product liability claims, and our prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.


Source: Auriga Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.